Navigation Links
Albemarle Optimizes Smallpox Drug Candidate for SIGA
Date:5/5/2008

and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. For more information about SIGA, please visit http://www.siga.com.

Albemarle Corporation is a leading global developer, manufacturer and marketer of highly engineered specialty chemicals for consumer electronics; petroleum and petrochemical processing; transportation and industrial products; pharmaceuticals; agricultural products; and construction and packaging materials. The Company operates in three business segments-Polymer Additives, Catalysts and Fine Chemicals, and serves customers in approximately 100 countries. Learn more about Albemarle at http://www.albemarle.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding Albemarle Corporation's business which are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's Annual Report on Form 10-K.


'/>"/>
SOURCE Albemarle Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
4. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
5. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
6. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
7. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
8. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
9. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
10. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
11. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 31, 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: ... field of regenerative medicine, today announced that the ... Chicago -based Rush University Medical Center in ... escalating doses of AST-OPC1 (oligodendrocyte progenitor cells) in ... cervical spinal cord injury (SCI). This represents the ...
(Date:8/31/2015)... 2015   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade cell and tissue ... media and a related cloud hosted ... smart shippers ("BioLife" or the "Company"), today ... biopharmaceutical company focused on developing and commercializing novel ...
(Date:8/28/2015)... , Aug. 28, 2015  With the heroin ... reaching deadlier heights, Jacksonville -based Lakeview ... Hemphill is helping to explain why fentanyl is ... approximately 40 to 50 times more potent than pharmaceutical ... users as heroin, the risk of death skyrockets. ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 2BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 3BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 4BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 5Lakeview Health's Dr. Philip Hemphill Explains Why Heroin Addicts Are Now Dying of Fentanyl Overdoses 2
... (OTCQX: DATA), a technology and services company focused on global ... its Vice President of Research and Development, Chris Wilke, has ... 2009 Society for Clinical Data Management (SCDM) Annual Conference which ... Mr. Wilke will be discussing Is 100% EDC Realistic? ...
... ThermalTherapeutic Systems, Inc., developers of a highly ... today the completion of $2.75 Million Series A ... funding by the Pittsburgh Life Sciences Greenhouse, and ... investments by the Pittsburgh Life Sciences Greenhouse and ...
Cached Medicine Technology:DATATRAK to Present at 2009 SCDM Annual Conference 2DATATRAK to Present at 2009 SCDM Annual Conference 3ThermalTherapeutic Systems Completes $2.75 Million Series A Financing With Originate Ventures 2
(Date:8/31/2015)... ... , ... The Lisle family law firm of Momkus McCluskey, LLC ... peers to earn a “Leading Lawyers” distinction. , The “Leading Lawyers” ... Illinois. The nomination process is based on statewide peer survey nominations and the approval ...
(Date:8/31/2015)... ... August 31, 2015 , ... Patients who thought about getting a hair ... in learning more about the procedure beyond the information found on the Internet can ... transplant surgeon Parsa Mohebi will be on hand to answer patients hair transplant questions ...
(Date:8/31/2015)... ... 2015 , ... Neuropsychiatric Disease and Treatment has ... near-infrared laser phototherapy ”. , As corresponding author Dr Theodore Henderson says “These ... with mostly palliative treatments only - and now we have shown real clinical ...
(Date:8/31/2015)... ... August 31, 2015 , ... Dr. Paul Kovatis of ... Doc.” , At OSSMC, Dr. Kovatis treats all surgical and non-surgical disorders of the ... to the entire musculoskeletal system, excluding the spine. , Dr. Paul Kovatis completed his ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... marketing communications company announced today that it has officially launched a new website ... new website and brand refresh are more closely aligned with the company’s strategic ...
Breaking Medicine News(10 mins):Health News:DuPage County Family Law Attorney Named Illinois Leading Lawyer 2Health News:Watch a Live Hair Transplant at Parsa Mohebi Hair Restoration’s Open House 2Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 2Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 3Health News:NJ Top Docs Presents, Dr. Paul Kovatis of Orthopedic Spine & Sports Medicine Center on his Five Year Anniversary as an "NJ Top Doc" 2Health News:Diablo Publications Launches New Company Website 2Health News:Diablo Publications Launches New Company Website 3
... all possible factors that could probably play a significant ... doctors worldwide for years together, // has homed on ... for triggering off the development of autism in children ... affects the communication skills and social interactions of an ...
... to a recent study, patients with ... improvements and less bloating on taking ... the first time that a randomized ... continued effect of an antibiotic for ...
... have a craving for white bread pause to hear this. ... excessive consumption of white bread could lead to cancer of ... flour. Researchers have come to conclusion that use of excessive ... to the circulation which in turn stimulates the release of ...
... demonstrated how intense struggle among the human immune system's T ... and take on a more virulent form, developing into the ... computer model of simultaneous virus and immune system evolution, also ... against the virus. The research, which is slated for ...
... a magic bullet for obesity — rimonabant (Acomplia) — does ... also helps lower cardiac risk factors, according to a review ... in July, and U.S. approval is pending before the Food ... suppressing the appetite by targeting the brain cells involved in ...
... of obsessive compulsive disorder in children and adolescents, according ... relieve the overall distress // and reduces the interference ... ,Further, the evidence indicates that cognitive behavioral therapy ... OCD, say lead researcher Richard O'Kearney and colleagues. ...
Cached Medicine News:Health News:HIV Takes Advantage of Rivalry among T cells 2Health News:HIV Takes Advantage of Rivalry among T cells 3Health News:Latest Weight-Loss Pill Offers Modest Results, Blocks 'Munchies' 2Health News:Latest Weight-Loss Pill Offers Modest Results, Blocks 'Munchies' 3Health News:Cognitive Behavioral Therapy Helps Children with Obsessive Compulsive Disorder 2Health News:Cognitive Behavioral Therapy Helps Children with Obsessive Compulsive Disorder 3
The Natural Selection family of specialty allografts is spinal concepts response to surgeon requests for spinal allograft devices to eliminate the need for painful autograft harvesting....
Transcranial vascular DWL doppler....
Transcranial vascular DWL doppler....
... Neurocare is a full-featured physiologic testing system offered ... contains many of the features of our flagship ... economical price. , ,The smaller size of the ... environment, the physician's office, a mobile service or ...
Medicine Products: